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Summary 
Objective: To estimate the comparative efficacy and safety of antiepileptic drugs (AEDs) in 
elderly with new-onset epilepsy. 
Methods: We searched electronic databases for randomized controlled trials (RCTs) of 
monotherapy AEDs to treat epilepsy in elderly. The following outcomes were analyzed: 
seizure freedom and withdrawal from the study for any cause at 6 and 12 months; withdrawal 
from the study for any adverse event (AE) at 12 months; occurrence of any AE at 12 months. 
Effect sizes were estimated by network meta-analyses within a frequentist framework. The 
hierarchy of competing interventions was established using the surface under the cumulative 
ranking curve (SUCRA) and mean ranks. 
Results: Five RCTs (1,425 patients) were included. Included AEDs were: carbamazepine 
immediate- and controlled- release (CBZ-IR, CBZ-CR), gabapentin (GBP), lacosamide 
(LCM), lamotrigine (LTG), levetiracetam (LEV), phenytoin (PHT), and valproic acid (VPA). 
At the pairwise and network meta-analyses, there were no differences in any of the 
comparison according to 6- and 12-month seizure freedom. The treatment with CBZ-IR and 
CBZ-CR was associated with a higher risk of withdrawal than LTG, LEV or VPA, and CBZ-
IR had the overall highest probability of discontinuation across all AEDs. According to 
SUCRA, LCM, LTG, and LEV had the greatest likelihood ranking best for seizure freedom at 
6 and 12 months. CBZ-CR and CBZ-IR had the highest probabilities of being worst for the 
12-month retention. CBZ-IR, CBZ-CR and GBP had the highest probabilities of withdrawal 
from the study for AEs, and VPA had the highest probability to be the best tolerated option. 
Significance: Although no significant difference in efficacy was found across treatments, 
LCM, LTG and LEV had the highest probability of ranking best for achieving seizure 
freedom. CBZ-IR and CBZ-CR showed a poor tolerability profile leading to higher 
withdrawal rates compared to LEV and VPA.  
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Key Points: 
 In this systematic review we estimated the comparative efficacy and safety of 
antiepileptic drugs in elderly with new-onset epilepsy. 
 No differences were found for 6- and 12-month seizure freedom, whilst CBZ-IR and 
CBZ-CR were withdrawn more frequently than other drugs. 
 LCM, LTG and LEV had the highest probability of ranking best for achieving seizure 
freedom.  
 CBZ-IR and CBZ-CR had a poor tolerability profile and higher withdrawal rates than 
LEV and VPA.  
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1. Introduction 
Epilepsy has a peak incidence in older age groups, with an annual incidence of 134 per 
100,000 in people aged ≥ 65 years.1 Due to the rapidly aging population, epilepsy in the 
elderly is increasingly encountered in clinical practice, and its incidence among this age group 
has actually increased in the recent decades.2 In this population, cerebrovascular disease 
represents the most commonly identified etiology, along with dementia, brain tumors, and 
trauma.3 The underlying cause remains, however, unknown in as many as 25-40% of the 
cases.4 
The management of new-onset epilepsy in the elderly is challenging, as ageing affects drug 
pharmacokinetics and pharmacodynamics, and increases the risk of adverse events; 
polytherapy for medical and psychiatric comorbidities is also common and further raises the 
risk of drug interactions and poor medication adherence.5,6 All these issues need to be 
carefully taken into account by physicians in the selection of the initial antiepileptic 
monotherapy. In this regard, the availability of data on the comparative efficacy and safety of 
antiepileptic drugs (AEDs) would provide useful clinical guidance for the management of 
elderly patients with new-onset epilepsy. So far, however, only few randomized controlled 
trials (RCTs) have been performed, and the evidence coming from direct head-to-head 
comparisons is limited.7 
In this study, we aimed to systematically review the currently available RCTs of AEDs used 
as monotherapy treatment for epilepsy in elderly patients, and estimate their comparative 
efficacy and safety by means of a network meta-analysis (NMA). 
 
2. Methods 
Results were reported according to the recommendations of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) extension statement 
for network meta-analyses8 (Appendix I). The review protocol was not previously registered. 
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Randomized controlled trials comparing any AED versus any comparator as monotherapy for 
newly diagnosed (incident) epilepsy (any type) in elderly patients (≥60 years) were included. 
Studies with other design or conducted in etiology-specific epilepsy (e.g., stroke or 
Alzheimer´s disease) were not included in the current analysis. 
The following electronic databases and data sources were systematically searched: 
1.MEDLINE (January 1966–2nd June 2019), accessed through PubMed; 
2.Cochrane Central Register of Controlled Trials (CENTRAL; accessed 2nd June 2019); 
3.EMBASE (accessed 2nd June 2019); 
4. Opengrey.eu (available at: www.opengrey.eu; accessed 2nd June 2019) 
Details of the search strategy are reported in Appendix II. All resulting titles and abstracts 
were evaluated, and any relevant article was considered. No language restrictions were 
adopted. 
Retrieved articles were independently assessed for inclusion by two review authors (FB, SL); 
any disagreement was resolved through discussion. The methodological quality of all 
included studies and the risk of bias were assessed as outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions version 5.1.09 (Appendix III). 
The following trial data were independently extracted by two review authors (FB, RN): main 
study author and date of publication; inclusion and exclusion criteria; number, age, and sex of 
participants for each treatment group; study phases; intervention details (tested drug and 
comparator). The following outcomes were considered:  
Efficacy outcomes 
1. seizure freedom (all seizure types) at 6 months (24 ± 2 weeks) and 12 months (52 ± 2 
weeks) from the start of the maintenance phase;  
2. withdrawal from the study for any cause at 6 months (24 ± 2 weeks) and 12 months 
(52 ± 2 weeks) from the start of the maintenance phase;  
Safety outcomes 
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1. Withdrawal from the study for any adverse event (AE) at 12 months from the start of 
the titration or maintenance phase;  
2. Occurrence of any AE at 12 months from the start of the titration or maintenance 
phase. 
First, we did pairwise meta-analyses for all outcomes, using a fixed-effects model. Second, 
we performed network meta-analyses within a frequentist framework assuming equal 
heterogeneity parameter τ across all comparisons.10 It is appropriate to use NMA if the 
assumption of transitivity (distributions of the potential effect modifiers, like study and 
patient-level covariates, are balanced across all pairwise comparisons) can be defended.11 We 
assessed the transitivity assumption looking at the similarities of studies in each comparison. 
Closed loops in the network were formed by multi-arm studies and, hence, we were not able 
to assess the agreement between direct and indirect evidence for a specific comparison 
(consistency assumption).12 Effect sizes were estimated as odds ratios (ORs) with their 95% 
confidence intervals (CIs). The hierarchy of competing interventions was established using 
the surface under the cumulative ranking curve (SUCRA) and mean ranks. All analyses were 
intention-to-treat. Data analysis was performed using STATA/IC 13.1 statistical package 
(StataCorp LP, College Station, TX, USA). 
 
3. Results 
We identified a total of 2,349 records  by database and trial registers searching (1,087 
EMBASE, 930 MEDLINE, 321 CENTRAL, 11 Opengrey.eu). After excluding duplicates 
(1,213) and reading title and abstracts, 14 RCTs were initially considered. After reading the 
full-text, 9 studies were eventually excluded (see Appendix IV). Hence, 5 RCTs were 
included (Figure 1), which recruited 1,425 patients with newly diagnosed epilepsy.13-18 One 
study16 reported post-hoc analyses of elderly participants’ data derived from a previous 
RCT18; one study, which included also younger participants, provided enough data on elderly 
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patients to be analyzed separately.17,19 The following comparisons were included in the RCTs: 
phenytoin (PHT) versus valproic acid (VPA),13 carbamazepine-immediate release (CBZ-IR) 
versus lamotrigine (LTG) versus gabapentin (GBP),14 carbamazepine-controlled release 
(CBZ-CR) versus LTG versus levetiracetam (LEV),15 LEV versus VPA and LEV versus 
CBZ-CR,16 and CBZ-CR versus lacosamide (LCM).17,19 Characteristics of the included trials 
and study participants are summarized in Table 1 and Table 2, respectively.  
 
3.1. Risk of bias of included studies. 
A summary of risk of bias assessment is reported in Appendix V and VI. All studies defined 
the method used for random sequence generation, and 4 provided the details of allocation 
concealment.14-17 One RCT did not perform a blinding of the participants and personnel (high 
risk of performance bias),13 and one was unblinded (participants, study personnel, and 
outcome assessors; high risk of performance and detection bias).16 Two studies were judged at 
high risk of selective reporting, as one was a post hoc analysis16 and the other did not provide 
results of all the specified primary and secondary outcomes.17  
 
3.2. Efficacy outcomes 
Only 3 RCTs provided data on seizure freedom at 6 and 12 months; they compared CBZ-CR 
versus LTG versus LEV,15 LEV versus VPA or LEV versus CBZ-CR,16 and CBZ-CR versus 
LCM.17,19 Figure 2 shows the network plots of treatment comparisons for the efficacy 
outcomes. At the pairwise meta-analyses, there were no differences in any of the comparison 
according to 6- and 12-month seizure freedom; CBZ-IR was associated with a higher rate of 
study withdrawal for any cause at 12 months than LTG (OR 2.29; 95% CI: 1.53 to 3.43) and 
GBP (OR: 0.57; 95% CI: 0.38 to 0.86), and LEV was associated with a lower risk of 12-
month study discontinuation in comparison to CBZ-CR (OR: 0.40; 95% CI: 0.28 to 0.59). 
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Also VPA was associated with a lower risk of study withdrawal for any cause at 12 months 
compared to CBZ-CR (OR: 0.34; 95% CI: 0.16 to 0.73) (Table e-1). 
Results of the network meta-analyses of efficacy outcomes are shown in Figure 3. No 
significant differences were noted between AEDs in the achievement of seizure freedom at 6 
months. There were non-significant trends favoring LCM over CBZ-CR (OR 1.79; 95% CI: 
0.83 to 3.86) and LTG over CBZ-CR (OR 1.38; 95% CI: 0.85 to 2.24). Similarly, no 
statistically significant differences were found across treatments for seizure freedom at 12 
months. A non-significant trend favoring LEV over CBZ-CR was found (OR 1.28; 95%CI: 
0.89 to 1.85). According to SUCRA, LCM, LTG and LEV had the greatest likelihood ranking 
best for seizure freedom at 6 and 12 months (Table 3 and Appendix VII). 
There was insufficient information on proportion of patients withdrawing from the study for 
any cause at 6 months to allow analyses. In comparison to CBZ-CR, LEV (0.40; 95% CI: 0.28 
to 0.59), VPA (0.40; 95% CI: 0.19 to 0.83) and LTG (0.59; 95% CI: 0.37 to 0.96) were 
associated with a lower rate of 12-month withdrawal for any cause. There were higher 
withdrawal rates for GBP than for LEV (1.93; 95% CI: 1.03 to 3.61), and for CBZ-IR 
compared to LEV (3.36; 95% CI: 1.79 to 6.31), VPA (3.37; 95% CI: 1.34 to 8.49), and LTG 
(2.29; 95% CI: 1.53 to 3.43). GBP had a better retention rate than CBZ-IR (OR 0.57; 95% CI: 
0.38 to 0.86). According to SUCRA, CBZ-CR and CBZ-IR had the highest probabilities of 
being worst for the 12-month retention. 
 
3.3. Safety outcomes 
All 5 RCTs provided data on withdrawal from the study for adverse events, whereas only 3 
studies provided data on 12-month occurrence of AEs. Figure 2 shows the network plots of 
treatment comparisons for the safety outcomes. At the pairwise meta-analyses, LEV and VPA 
were associated with a lower risk of 12-month study withdrawal due to AEs than CBZ-CR 
(OR 0.33; 95% CI: 0.21 to 0.51 and OR: 020; 95% CI: 0.07 to 0.54, respectively); GBP had 
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lower discontinuation rate than CBZ-IR (OR: 0.62; 95% CI: 0.39 to 0.97), whereas CBZ-IR 
and GBP had higher rates of discontinuation in comparison to LTG (OR: 3.27; 95% CI: 1.94 
to 5.52 and OR 2.02; 95% CI: 1.17 to 3.48). The risk of AE occurrence at 12 months was 
lower with VPA than CBZ-CR (OR: 0.37; 95% CI: 0.17 to 0.79) (Table e-1). 
Results of the network meta-analyses of efficacy outcomes are shown in Figure 3. 
With regard to the outcome of 12-month study withdrawal due to AEs, LEV and VPA 
performed better than CBZ-CR (OR: 0.33; 95% CI: 0.21 to 0.51 and OR: 0.23; 95% CI: 0.08 
to 0.61, respectively). CBZ-IR was associated with a higher rate of discontinuation than CBZ-
CR (OR: 2.18; 95% CI: 1.03 to 4.61), LEV (OR: 6.68; 95% CI: 3.08 to 14.49), VPA (OR: 
9.68; 95% CI: 2.87 to 32.65), and LTG (OR: 3.27; 95% CI: 1.94 to 5.52 ); GBP was 
associated with a higher risk of withdrawal than LEV (OR: 4.12; 95% CI: 1.87 to 9.08), VPA 
(OR: 5.96; 95% CI: 1.75 to 20.33), and LTG (OR: 2.01; 95% CI: 1.17 to 3.48). Treatment 
with LTG had a higher risk of 12-mont withdrawal than LEV (OR: 2.04; 95% CI: 1.15 to 
3.62). According to SUCRA, CBZ-IR, CBZ-CR and GBP had the highest probabilities of 
withdrawal from the study for AEs (or, conversely, the lowest probability of being retained) 
(Table 3 and Appendix VII). VPA was associated with a lower risk of occurrence of AEs at 
12 months in comparison to CBZ-CR (OR: 0.40; 95% CI: 0.20 to 0.82); conversely, LTG was 
associated with higher occurrence of AEs than VPA (OR: 4.23; 95% CI: 1.44 to 12.40). 
According to SUCRA, the use of VPA had the highest probabilities of being the best tolerated 
option. 
 
4. Discussion 
One main finding of the current study was the lack of any clear-cut difference across AEDs in 
their comparative efficacy, estimated as the likelihood of seizure freedom at 6 and 12 months, 
when given as monotherapy in new-onset epilepsy in the elderly. Although this might reflect 
lack of statistical power and false negative results,20 equi-effectiveness should be considered. 
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Remarkably, all the RCTs conducted so far in elderly with new-onset epilepsy and adopting a 
superiority design failed to demonstrate any difference with the active comparator, the only 
exception being one study showing a higher retention rate for LEV than for CBZ-CR, 
although without difference in seizure freedom.15 Hence, the possibility that the efficacy 
profile across different AEDs is similar should not be disregarded. It is, however, also worth 
to notice that a not significant trend favoring LCM, LTG and LEV over CBZ-CR was found.  
The current NMA has also shown that the treatment with CBZ-IR and CBZ-CR was 
associated with a higher risk of withdrawal than LTG, LEV or VPA, and CBZ-IR had the 
overall higher probability of discontinuation across all treatment options. The use of 
extended-release CBZ is widely recommended to facilitate compliance, minimize peak and 
trough fluctuations, and obtain relatively stable blood concentrations, reducing the risk of 
AEs, and increasing the compliance by allowing once or twice daily intake.21,22 However, 
these recommendations were based on pharmacokinetic considerations rather than clinical 
evidence, due to the lack of direct head-to-head comparisons between IR and CR 
formulations. In this regard, the current analyses provided indirect evidence to support the 
preferential use of CBZ-CR over CBZ-IR due to the lower risk of withdrawal due to AEs.  
We could not assess whether CBZ preparations used in the RCTs came from the same drug 
manufacturer, as this information was not explicitly reported in all studies (Appendix VIII). 
Furthermore, the included studies did not systematically measured CBZ serum levels, making 
it difficult to establish whether differences in absorption rates of CBZ across the studies may 
have contributed to the relatively poorer tolerability of this drug compared to other AEDs.  
This NMA is the first one to compare the efficacy and safety of AEDs used as monotherapy 
treatment for epilepsy in elderly patients, and updates and build up the currently available 
systematic reviews of evidence. In 2013, the Commission on Therapeutic Strategies of the 
International League Against Epilepsy (ILAE) has reviewed the available evidence of AEDs 
efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes in 
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different age groups.23 This review concluded that GBP and LTG have established (level of 
evidence: A) long-term efficacy or effectiveness as initial monotherapy for elderly with newly 
diagnosed or untreated epilepsy; CBZ was found to be possibly (level C), and topiramate and 
VPA as potentially (level D) efficacious/effective. However, no information on LEV and 
LCM was available at that time, as results of RCTs on these drugs had yet to be published. 
Very recently, a systematic review of the literature found that in elderly with new-onset 
epilepsy, LTG was better tolerated than CBZ, whereas LEV was associated with higher 
seizure freedom rates than LTG, without significant differences in tolerability; no significant 
differences were found between CBZ and LEV for efficacy and tolerability.7 Notably, results 
of this review should be read with caution because of the wide entry criteria adopted (e.g., 
AEDs as monotherapy or add-on treatments) and the inclusion of RCTs that were very 
different in their clinical and methodological characteristics. Conversely, in the present NMA 
we used very strict inclusion criteria in order to minimize as much as possible any source of 
clinical and methodological heterogeneity, which could have resulted in an increased overall 
risk of inaccuracy. Some limits should be however considered while interpreting the findings, 
as the inclusion of a limited number of studies exploring only a set of the approved AEDs, the 
lack of data according to drug dosage, and the short length of the follow-up, which could not 
allow to identify long-term adverse events (e.g., parkinsonism associated with chronic VPA 
use24,25).   
 
5. Conclusion 
In conclusion, this study provides evidence that CBZ, either in its IR or CR formulation, has a 
poor tolerability profile leading to higher withdrawal rates compared to newer AEDs, mostly 
VPA and LEV. Although no significant difference in efficacy was found across treatments, 
LCM, LTG and LEV had the highest probability of ranking best for achieving seizure 
freedom. NMAs are not substitutes for clinical trials directly comparing two or more drugs, 
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but they may offer reliable evidence of the relative efficacy and safety,20,26 provide useful 
information about the hierarchy of competing interventions and represent a complementary 
guide to inform physicians in their clinical decision-making.  
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Figure and table legends 
 
Figure 1: Study flow diagram 
Figure 2: Network of treatment comparisons for efficacy and safety 
Figure 3: Interval plots for the efficacy and safety outcomes 
 
Table 1: Study characteristics 
Table 2: Clinical characteristics of patients included in each trial 
Table 3: Ranking according to SUCRA and mean rank for the efficacy and safety outcomes 
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Table 1: Study characteristics 
 
Study Study design Inclusion criteria Exclusion criteria Comparisons, daily 
dose, mg/day 
[range] 
(participants, n) 
Study duration, 
weeks; phases 
Craig and Tallis, 
199413 
Single center, 
randomised, study 
investigator and 
outcome assessor 
blinded trial 
≥1 unprovoked 
GTCS or ≥ 2 focal 
seizures, age > 60 
years 
Progressive 
neurological disease 
PHT mean 247 
mg/day [175‐275] 
(n=20) versus VPA 
mean 688 mg/day 
[400‐1000] (n=18) 
52 weeks 
Rowan et al., 
200514 
Multicentre, 
randomised, 
double-blind trial 
Newly diagnosed 
epilepsy with 
seizures of any 
type, age ≥ 65 
years 
Progressive 
neurological disease 
CBZ-IR 600 mg/day 
(n=198) versus LTG 
150 mg/day (n=200) 
versus GBP 1500 
mg/day (n=195) 
52 weeks 
 
1. Titration: 6 
weeks 
2. Maintenance: 46 
weeks 
Werhahn et al., 
201515 
Multicentre, 
randomised, 
double-blind trial 
Patients aged ≥60 
years with new-
onset focal 
epilepsy; no or <4 
weeks previous 
AED treatment 
Acute symptomatic 
seizures; previous 
treatment with 
VPA; renal 
insufficiency; 
increased liver 
enzymes or 
bilirubin; dementia; 
drug or alcohol 
abuse; psychiatric 
condition requiring 
legal guardianship; 
reduced life 
expectancy 
CBZ-CR 400 
mg/day (n=120) 
versus LTG 100 
mg/day (n=117) 
versus LEV 1000 
mg/day (n=122) 
58 weeks 
 
1. Titration: 6 
weeks 
2. Maintenance: 52 
weeks  
Pohlmann-Eden et 
al., 201616 
Multicentre, 
randomised, 
unblinded trial 
Newly diagnosed, 
unprovoked 
seizures, age ≥16 
years (limited to ≥ 
60 years in our 
analysis) 
Previous treatment 
with LEV, VPA or 
CBZ for any 
indication or 
treatment for 
epilepsy with any 
other AED in the 
last 6 months 
Two parallel groups: 
 
LEV 1000 mg/day 
(n=48) versus VPA 
1000 mg/day (n=52) 
 
LEV 1,000 mg/day 
(n=104) versus CBZ-
CR 600 mg/day 
(n=103) 
52 weeks 
 
1. Titration: 2 
weeks 
2. Maintenance: 50 
weeks 
Baulac et al., 
201717; Rosenow 
et al., 201719 
Multicentre, 
randomised, 
double-blind, non-
inferiority trial  
Newly diagnosed, 
untreated epilepsy 
(focal unprovoked 
or GTCS), age ≥16 
years (limited to ≥ 
65 years in our 
analysis)  
Seizure clusters or 
status epilepticus; 
conversion disorders 
or other non-
epileptic ictal 
events; prior 
treatment with LCM 
or CBZ; drugs 
affecting CBZ 
metabolism; women 
not using 
contraception 
CBZ-CR 400 
mg/day (n=57) 
versus LCM 200 
mg/day (n=62) 
≥30 weeks 
 
1. Screening: 1 
week 
2. Titration: 2 
weeks 
3. Stabilization: 1 
week 
4. Evaluation with 
flexible dosing: 26 
weeks 
5. Maintenance: 26 
weeks 
Abbreviations: AED: antiepileptic drug; CBZ: carbamazepine; CBZ-CR: carbamazepine controlled-
release; CBZ-IR: carbamazepine immediate-release; GBP: gabapentin; GTCS: generalized tonic-
clonic seizure; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine; PHT: phenytoin; VPA: 
valproic acid. 
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Table 2: Clinical characteristics of patients included in each trial 
 
Study Number of participants (ITT) Proportion of women, % Mean age, years, mean ± SD/ 
[range] 
Craig and Tallis, 199413 38 Not reported PHT 74.9 [67‐84] 
VPA 76.3 [62‐88] 
Rowan et al., 200514 590 CBZ-IR 6.2% 
LTG 2.5% 
GBP 3.3% 
CBZ-IR 71.9 ± 7.7 
LTG 71.9 ± 7.4 
GBP 72.9 ± 7.5 
Werhahn et al., 201515 359  CBZ-CR 45.8% 
LTG 41.0% 
LEV 33.6% 
CBZ-CR 71.7 ± 6.7 
LTG 70.7 ± 7.4 
LEV 71.8 ± 7.5 
Pohlmann-Eden et al., 
201616 
307  Comparison LEV versus VPA:  
LEV 47.9% 
VPA 36.5% 
 
Comparison LEV versus CBZ‐
CR:  
LEV 42.3% 
CBZ‐CR 47.6% 
Comparison LEV versus VPA:  
LEV 71.1 ± 6.8 
VPA‐ER 70.4 ± 6.5 
 
Comparison LEV versus CBZ‐
CR:  
LEV 68.8 ± 5.9 
CBZ‐CR 69.3 ± 6.4 
Baulac et al., 2017;17 
Rosenow et al., 201719 
119 Not reported ≥ 65 years; no other details 
available 
 
Abbreviations: CBZ: carbamazepine; CBZ-CR: carbamazepine controlled-release; CBZ-IR: 
carbamazepine immediate-release; GBP: gabapentin; ITT: intention-to-treat; LEV: levetiracetam; 
LTG: lamotrigine; PHT: phenytoin; SD: standard deviation; VPA: valproic acid. 
  
Accepted author manuscript. Published in fully edited version in Epilepisa 2019 Oct 13.  
Publisher DOI: 0.1111/epi.16366  
 
Table 3: Ranking according to SUCRA and mean rank for the efficacy and safety 
outcomes 
a) Seizure freedom at 6 months 
Treatment SUCRA Mean rank 
CBZ-CR 15.9 4.4 
LCM 81.5 1.7 
LEV 54.9 2.8 
VPA 34.6 3.6 
LTG 63.2 2.5 
 
b) Seizure freedom at 12 months 
Treatment SUCRA Mean rank 
CBZ-CR 25.1 4.0 
LCM 71.9 2.1 
LEV 68.1 2.3 
VPA 34.6 3.6 
LTG 50.4 3.0 
 
c) Withdrawal for any cause at 12 months 
Treatment SUCRA Mean rank 
CBZ-CR 17.9 6.7 
LCM 47.7 4.7 
LEV 80.1 2.4 
VPA 76.3 2.7 
LTG 55.8 4.1 
CBZ-IR 4.1 7.7 
GBP 35.0 5.6 
PHT 83.1 2.2 
 
d) Withdrawal for any adverse event at 12 months 
Treatment SUCRA Mean rank 
CBZ-CR 35.2 5.5 
LCM 51.1 4.4 
LEV 85.5 2.0 
VPA 94.5 1.4 
LTG 58.5 3.9 
CBZ-IR 3.4 7.8 
GBP 24.0 6.3 
PHT 47.7 4.7 
 
e) Any adverse event at 12 months 
Treatment SUCRA Mean rank 
CBZ-CR 35.1 3.6 
LCM 48.5 3.1 
LEV 61.6 2.5 
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VPA 96.6 1.1 
LTG 8.2 4.7 
 
Abbreviations: CBZ: carbamazepine; CBZ-CR: carbamazepine controlled-release; CBZ-IR: 
carbamazepine immediate-release; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; 
LTG: lamotrigine; PHT: phenytoin; SUCRA: surface under the cumulative ranking curve; 
VPA: valproic acid.  
Higher SUCRA values correspond to higher probabilities of better efficacy/tolerability. 
 
 
 
Figure 1. 
 
 
 
 
Figure 2. Network of treatment comparisons for efficacy and safety outcomes 
 
a) Seizure freedom at 6 months 
 
b) Seizure freedom at 12 months 
 
 
 
 
c) Withdrawal for any cause at 12 months 
 
 
 
d) Withdrawal for any adverse event at 12 months 
 
 
 
 
e) Any adverse event at 12 months 
 
The width of the lines is proportional to the inverse of the variance of the comparison 
treatment effect and the size of every circle is proportional to the number of randomly 
assigned participants.  
Abbreviations: CBZ-CR: carbamazepine controlled-release; CBZ-IR: carbamazepine 
immediate-release; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: 
lamotrigine; PHT: phenytoin; VPA: valproic acid. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Interval plots for the efficacy and safety outcomes 
a) Seizure freedom at 6 months 
 
b) Seizure freedom at 12 months 
 
 
c) Withdrawal for any cause at 12 months 
 
d) Withdrawal for any adverse event at 12 months 
 
 
 
 
e) Any adverse event at 12 months 
 
Abbreviations: CBZ-CR: carbamazepine controlled-release; CBZ-IR: carbamazepine 
immediate-release; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: 
lamotrigine; PHT: phenytoin; VPA: valproic acid. 
 
 
 
 
 
 
Figure e-1. Two-dimensional graphs of efficacy versus tolerability at 12 months 
 
A) Seizure freedom versus withdrawal for any adverse event  
 
  
B) Seizure freedom versus occurrence of any adverse event  
 
Effect sizes for individual drugs are represented by colored nodes, with bars representing corresponding 95% confidence intervals. 
  
Table e-1: Results of the pairwise meta-analyses for the efficacy and safety outcomes 
 
a) Seizure freedom at 6 months 
Comparison Study Odds ratio (95% CI) p value 
LCM vs. CBZ-
CR 
Baulac et al., 2017 1.79 (0.83-3.86) 0.138 
LEV vs. CBZ-
CR 
Pohlmann-Eden et al., 2016; 
Werhahn et al., 2015 
1.28 (0.89-1.85) 0.181 
VPA vs. CBZ-
CR 
Pohlmann-Eden et al., 2016 1.02 (0.51-2.03) 0.966 
VPA vs. LEV Pohlmann-Eden et al., 2016 0.90 (0.47-1.74) 0.761 
LTG vs. CBZ-
CR 
Werhahn et al., 2015 1.48 (0.88-2.47) 0.139 
LTG vs. LEV Werhahn et al., 2015 1.01 (0.61-1.69) 0.956 
 
 
b) Seizure freedom at 12 months 
Comparison Study Odds ratio (95% CI) p value 
LCM vs. CBZ-
CR 
Baulac et al., 2017 1.43 (0.69-2.95) 0.335 
LEV vs. CBZ-
CR 
Pohlmann-Eden et al., 2016;  
Werhahn et al., 2015 
1.28 (0.89-1.85) 0.180 
VPA vs. CBZ-
CR 
Pohlmann-Eden et al., 2016 0.94 (0.48-1.85) 0.855 
VPA vs. LEV Pohlmann-Eden et al., 2016 0.84 (0.44-1.60) 0.596 
LTG vs. CBZ-
CR 
Werhahn et al., 2015 1.25 (0.73-2.13) 0.411 
LTG vs. LEV Werhahn et al., 2015 0.84 (0.50-1.41) 0.513 
 
 
c) Withdrawal for any cause at 12 months 
Comparison Study Odds ratio (95% CI) p value 
LCM vs. CBZ-
CR 
Baulac et al., 2017 0.65 (0.32-1.36) 0.254 
PHT vs. VPA Craig et al., 1994 0.66 (0.14-2.93) 0.575 
LEV vs. CBZ-
CR 
Pohlmann-Eden et al., 2016;  
Werhahn et al., 2015 
0.40 (0.28-0.59) <0.001 
VPA vs. CBZ-
CR 
Pohlmann-Eden et al., 2016 0.34 (0.16-0.73) 0.005 
VPA vs. LEV Pohlmann-Eden et al., 2016 1.71 (0.55-2.49) 0.682 
CBZ-IR vs. 
LTG  
Rowan et al., 2005 2.29 (1.533-3.43) <0.001 
GBP vs. LTG Rowan et al., 2005 1.31 (0.88-1.96) 0.177 
GBP vs. CBZ-
IR 
Rowan et al., 2005 0.57 (0.38-0.86) 0.007 
LTG vs. CBZ-
CR 
Werhahn et al., 2005 0.68 (0.41-1.13) 0.135 
LTG vs. LEV  Werhahn et al., 2015 1.28 (0.76-2.14) 0.353 
 
 
 
d) Withdrawal for any adverse event at 12 months 
Comparison Study Odds ratio (95% CI) p value 
LCM vs. CBZ-
CR 
Baulac et al., 2017 0.74 (0.32-1.74) 0.493 
PHT vs. VPA Craig et al., 1994 3.43 (0.59-19.80) 0.168 
LEV vs. CBZ-
CR 
Pohlmann-Eden et al., 2016; 
Werhahn et al., 2015 
0.33 (0.21-0.51) <0.001 
VPA vs. CBZ-
CR 
Pohlmann-Eden et al., 2016 0.20 (0.07-0.54) 0.002 
VPA vs. LEV Pohlmann-Eden et al., 2016 0.85 (0.30.2.42) 0.753 
CBZ-IR vs. 
LTG  
Rowan et al., 2005 3. 27 (1.94-5.52) <0.001 
GBP vs. LTG Rowan et al., 2005 2.02 (1.17-3.48) 0.012 
GBP vs. CBZ-
IR 
Rowan et al., 2005 0.62 (0.39-0.97) 0.037 
LTG vs. CBZ-
CR 
Werhahn et al., 2005 0.75 (0.43-1.31) 0.312 
LTG vs. LEV  Werhahn et al., 2015 1.71 (0.92-3.20) 0.091 
 
e) Any adverse event at 12 months 
Comparison Study Odds ratio (95% CI) p value 
LCM vs. CBZ-
CR 
Baulac et al., 2017 0.87 (0.33-2.28) 0.776 
LEV vs. CBZ-
CR 
Pohlmann-Eden et al., 2016; 
Werhahn et al., 2015 
0.75 (0.46-1.23) 0.256 
VPA vs. CBZ-
CR 
Pohlmann-Eden et al., 2016 0.37 (0.17-0.79) 0.010 
VPA vs. LEV Pohlmann-Eden et al., 2016 0.56 (0.28-1.10) 0.091 
LTG vs. CBZ-
CR 
Werhahn et al., 2015 1.89 (0.72-4.92) 0.191 
LTG vs. LEV Werhahn et al., 2015 2.04 (0.79-5.24) 0.140 
 
Abbreviations: AED: antiepileptic drug; CBZ: carbamazepine; CBZ-CR: carbamazepine controlled-release; CBZ-IR: carbamazepine immediate-release; 
CI: confidence interval; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine; OR: odds ratio; PHT: phenytoin; VPA: valproic acid. 
 
 
 
  
Appendix I: PRISMA checklist 
 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
6 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
7 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
7 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
7 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
8 
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Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
8 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
8 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  9 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  9-11 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  9 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  - 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
11-12 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  13 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
13 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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 Appendix II: Search strategy for different databases 
 
EMBASE and MEDLINE: 
'elderly randomized' OR (('elderly'/exp OR elderly) AND 'randomized controlled trial' AND (epilep* OR seizur*)) 
 
CENTRAL: 
elderly (epilep* OR seizur*) 
 
Opengrey.eu 
elderly (epilep* OR seizur*) 
  
Appendix III: Excluded studies with reasons for exclusion 
 
Study Reference Reason(s) for exclusion 
Nieto-Barrera et al., 
2001 
Epilepsy Res 2001;46:145–55 Timepoints for outcome assessment different from inclusion criteria 
Gilad et al., 2007 Clin Neuropharmacol. 2007; 
30:189– 95. 
Etiology-specific epilepsy (stroke) 
Saetre et al., 2007 Epilepsia 2007;48:1292–302 Timepoints for outcome assessment different from inclusion criteria 
Ramsay et al., 2008 Epilepsia. 2008;59:1180-5 No monotherapy trial 
Cumbo et al., 2010 Epilepsy Behav. 2010;17:461-6 Timepoints for outcome assessment different from inclusion criteria; etiology-specific 
epilepsy (dementia) 
Zhang et al., 2011 J Int Med Res. 2011;39:408-15 No monotherapy trial 
Consoli et al., 2012 Cerebrovasc Dis. 2012;34:282– 9 Etiology-specific epilepsy (stroke) 
Leppik et al., 2014 Epilepsy Res. 2015;110:216–20 No monotherapy trial 
Brodie et al., 2016 Epilepsy Res. 2016;127:114–8 No monotherapy trial 
 
  
Appendix IV: Assessment of risk of bias, adopted from the Cochrane Handbook 
 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Higgins JPT and Green S, editors. The Cochrane 
Collaboration, 2011. Available at http://handbook-5-1.cochrane.org/.  
 
 
Domain and corresponding risk of bias Description 
Generation of a randomised sequence 
(selection bias, biased allocation to 
interventions)  
The investigators describe the method used 
to generate the sequence generation process 
in sufficient detail to allow an assessment of 
whether it should produce comparable 
groups. 
Allocation concealment (selection bias, 
biased allocation to interventions due to 
inadequate concealment of allocations prior 
to assignment) 
The investigators describe the method used 
to conceal the allocation sequence in 
sufficient detail to determine whether 
intervention allocations could have been 
foreseen in advance of, or during, 
enrolment. 
Blinding of participants and personnel 
(performance bias due to knowledge of the 
allocated interventions by participants and 
personnel during the study) 
The investigators describe the method used 
to blind study participants and personnel to 
prevent them from knowing the allocated 
interventions. 
Blinding of outcome assessment (detection 
bias due to knowledge of the allocated 
interventions by outcome assessors) 
The investigators describe the method used 
to blind outcome assessors to prevent them 
from knowing the allocated interventions. 
Incomplete outcome data (attrition bias 
due to amount, nature or handling of 
incomplete outcome data.) 
The outcome data is complete for each 
participants with regard to each outcome. 
Missing outcome data or exclusions from 
the analysis are taken into consideration, 
assessing their potential impact on the study 
results.  
Selective reporting (reporting bias due to 
selective outcome reporting) 
The published reports include all expected 
outcomes, including those that were pre-
specified. 
 
  
Appendix V: Summary of risk of bias in included studies 
 
 
 
  
Appendix VI: Risk of bias graph (review authors' judgements about each risk of bias item presented as percentages across all included studies) 
 
 
  
Appendix VII: Ranking according to SUCRA for the efficacy and safety outcomes 
 
f) Seizure freedom at 6 months 
 
 
g) Seizure freedom at 12 months 
 
h) Withdrawal for any cause at 12 months 
 
 
i) Withdrawal for any adverse event at 12 months 
 
 
 
j) Any adverse event at 12 months 
 
Abbreviation: SUCRA:surface under the cumulative ranking curve. 
  
Appendix VIII: Details of carbamazepine preparation and manufacturing drug company 
 
Study CBZ 
formulation 
Carbamazepine preparation and manufacturing drug company 
Rowan et al., 200514 CBZ-IR  NR 
Werhahn et al., 201515 CBZ-CR  Carbamazepine Sandoz Retard 200 mg tablets (Sandoz International GmbH, Holzkirchen, Germany); subsequently 
replaced by bioequivalent Tegretol® Retard by Novartis, Basel, Switzerland during the study since the firs became 
unavailable 
Pohlmann-Eden et al., 
201616 
CBZ-CR  Novartis, Switzerland 
Baulac et al., 201717; 
Rosenow et al., 201719 
CBZ-CR  Tegretol® Retard Tablets 200 mg 
 
 
Abbreviations: CBZ-CR: carbamazepine controlled-release; CBZ-IR: carbamazepine immediate-release; NR: not explicitly reported. 
 
